A cost-utility analysis of risk model-guided versus physician’s choice antiemetic prophylaxis in patients receiving chemotherapy for early-stage breast cancer: a net benefit regression approach
Crossref DOI link: https://doi.org/10.1007/s00520-017-3658-z
Published Online: 2017-03-09
Published Print: 2017-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Thavorn, Kednapa http://orcid.org/0000-0003-4738-8447
Coyle, Doug
Hoch, Jeffrey S.
Vandermeer, Lisa
Mazzarello, Sasha
Wang, Zhou
Dranitsaris, George
Fergusson, Dean
Clemons, Mark
License valid from 2017-03-09